BLCM Bellicum Pharmaceuticals Inc.

3.67
+0.08  (+2%)
Previous Close 3.59
Open 3.61
Price To Book 1.72
Market Cap 159135454
Shares 43,361,159
Volume 558,552
Short Ratio
Av. Daily Volume 427,603

SEC filingsSee all SEC filings

  1. 8-K - Current report 181233889
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163201
  3. 8-K - Current report 181163083
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181115098
  5. 424B5 - Prospectus [Rule 424(b)(5)] 181110864

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted 91% event-free survival (EFS) rate at 180 days at ASH December 2018. Final data 2019.
BPX-501
Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer
Phase 1 initial data released December 14, 2018 at ESMO noted 2/6 patients had tumor shrinkage >20%.
BPX-601
Pancreatic cancer
Phase 1/2 commenced March 2017. Initial data 2019.
BPX-701
PRAME (preferentially-expressed antigen in melanoma) -expressing melanoma, sarcomas and neuroblastoma cancer
Phase 2/3 trial to be initiated late-2018/ early-2019.
Rivo-cel
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

Latest News

  1. Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO
  2. Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer
  3. Novan Announces Top-Line Data From Mid-Stage Molluscum Study
  4. Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel
  5. Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
  6. Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018
  7. Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
  8. Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3
  9. Before You Buy Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), Consider Its Volatility
  10. Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference
  11. Bellicum Pharmaceuticals (BLCM) Reports Q3 Loss, Tops Revenue Estimates
  12. Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting
  13. Report: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications — New Horizons, Emerging Trends, and Upcoming Developments
  14. Edited Transcript of BLCM earnings conference call or presentation 7-Aug-18 9:00pm GMT
  15. Bellicum Pharmaceuticals Inc to Host Earnings Call

SEC Filings

  1. 8-K - Current report 181233889
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163201
  3. 8-K - Current report 181163083
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181115098
  5. 424B5 - Prospectus [Rule 424(b)(5)] 181110864
  6. 8-K - Current report 181110790
  7. EFFECT - Notice of Effectiveness 181035795
  8. CORRESP [Cover] - Correspondence
  9. UPLOAD [Cover] - SEC-generated letter
  10. S-3 - Registration statement under Securities Act of 1933 18998794